We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Halozyme Therapeutics Incorporated | NASDAQ:HALO | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.09 | 0.23% | 39.91 | 37.00 | 45.00 | 40.74 | 39.79 | 40.67 | 902,802 | 05:00:06 |
From May 2019 to May 2024
Halozyme Therapeutics Inc. reached a global collaboration and licensing agreement with AbbVie Inc. potentially valued at $1.19 billion to develop and commercialize products that combine AbbVie's treatments and Halozyme's Enhanze drug-delivery technology.
Halozyme shares rose 7% to $17.99 in recent premarket trading.
Under the agreement, San Diego-based Halozyme will receive an upfront payment of $23 million following by potential milestone payments of about $130 million each for as many as nine collaboration targets.
The biotechnology company's Enhanze platform helps in the dispersion and absorption of other injected therapeutic drugs.
Write to Tess Stynes at tess.stynes@wsj.com
Access Investor Kit for Halozyme Therapeutics, Inc.
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US40637H1095
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Halozyme Therapeutics Chart |
1 Month Halozyme Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
